Two Sigma Investments, LP Editas Medicine, Inc. Transaction History

Two Sigma Investments, LP

  • $42.3 Billion
  • Q3 2024

A detailed history of Two Sigma Investments, LP transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Two Sigma Investments, LP holds 1,358,589 shares of EDIT stock, worth $3.31 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
1,358,589
Previous 540,588 151.32%
Holding current value
$3.31 Million
Previous $2.52 Million 83.52%
% of portfolio
0.01%
Previous 0.01%

Shares

26 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024
BUY
$3.39 - $5.96 $2.77 Million - $4.88 Million
818,001 Added 151.32%
1,358,589 $4.63 Million
Q2 2024

Aug 14, 2024
SELL
$4.67 - $7.28 $3.96 Million - $6.17 Million
-847,394 Reduced 61.05%
540,588 $2.52 Million
Q1 2024

May 15, 2024
SELL
$7.03 - $11.07 $487,966 - $768,390
-69,412 Reduced 4.76%
1,387,982 $10.3 Million
Q4 2023

Feb 14, 2024
BUY
$6.25 - $11.11 $1.21 Million - $2.14 Million
192,806 Added 15.25%
1,457,394 $14.8 Million
Q3 2023

Nov 14, 2023
BUY
$6.92 - $9.31 $1.92 Million - $2.59 Million
278,168 Added 28.2%
1,264,588 $9.86 Million
Q2 2023

Aug 14, 2023
BUY
$6.36 - $11.47 $1.76 Million - $3.18 Million
277,511 Added 39.15%
986,420 $8.12 Million
Q1 2023

May 15, 2023
SELL
$7.03 - $11.53 $1.71 Million - $2.81 Million
-243,897 Reduced 25.6%
708,909 $5.14 Million
Q4 2022

Feb 14, 2023
SELL
$8.32 - $13.21 $451,351 - $716,629
-54,249 Reduced 5.39%
952,806 $8.45 Million
Q3 2022

Nov 14, 2022
BUY
$12.16 - $19.42 $3.82 Million - $6.09 Million
313,759 Added 45.26%
1,007,055 $12.3 Million
Q2 2022

Aug 15, 2022
SELL
$9.99 - $21.35 $2.49 Million - $5.31 Million
-248,796 Reduced 26.41%
693,296 $8.2 Million
Q1 2022

May 16, 2022
SELL
$14.08 - $27.63 $277,826 - $545,195
-19,732 Reduced 2.05%
942,092 $17.9 Million
Q4 2021

Feb 14, 2022
BUY
$26.55 - $40.57 $15.5 Million - $23.7 Million
583,709 Added 154.37%
961,824 $25.5 Million
Q3 2021

Nov 15, 2021
BUY
$39.27 - $72.94 $5.12 Million - $9.51 Million
130,394 Added 52.64%
378,115 $15.5 Million
Q2 2021

Aug 16, 2021
SELL
$31.29 - $56.64 $17.7 Million - $32.1 Million
-566,169 Reduced 69.56%
247,721 $14 Million
Q1 2021

May 17, 2021
BUY
$39.71 - $90.58 $29.1 Million - $66.5 Million
733,936 Added 917.95%
813,890 $34.2 Million
Q4 2020

Feb 16, 2021
SELL
$27.07 - $84.35 $8.26 Million - $25.7 Million
-305,225 Reduced 79.24%
79,954 $5.61 Million
Q3 2020

Nov 16, 2020
SELL
$28.06 - $37.16 $2.39 Million - $3.17 Million
-85,291 Reduced 18.13%
385,179 $10.8 Million
Q2 2020

Aug 14, 2020
BUY
$18.5 - $34.34 $1.69 Million - $3.13 Million
91,207 Added 24.05%
470,470 $13.9 Million
Q1 2020

May 15, 2020
SELL
$14.88 - $32.78 $1.99 Million - $4.39 Million
-133,969 Reduced 26.1%
379,263 $7.52 Million
Q4 2019

Feb 14, 2020
BUY
$19.49 - $32.63 $3.99 Million - $6.67 Million
204,564 Added 66.27%
513,232 $15.2 Million
Q3 2019

Nov 14, 2019
BUY
$22.49 - $26.81 $2.95 Million - $3.52 Million
131,130 Added 73.86%
308,668 $7.02 Million
Q2 2019

Aug 14, 2019
BUY
$20.48 - $27.76 $3.1 Million - $4.2 Million
151,155 Added 572.93%
177,538 $4.39 Million
Q1 2019

May 15, 2019
SELL
$19.43 - $26.41 $2.25 Million - $3.05 Million
-115,548 Reduced 81.41%
26,383 $645,000
Q4 2018

Feb 14, 2019
BUY
$18.19 - $31.79 $2 Million - $3.5 Million
110,201 Added 347.31%
141,931 $3.23 Million
Q3 2018

Nov 14, 2018
SELL
$27.65 - $38.39 $2.33 Million - $3.23 Million
-84,124 Closed
0 $0
Q2 2018

Aug 14, 2018
BUY
$31.4 - $41.01 $2.64 Million - $3.45 Million
84,124 New
84,124 $3.01 Million

Others Institutions Holding EDIT

# of Institutions
247
Shares Held
57M
Call Options Held
410K
Put Options Held
394K
View Full List

About Editas Medicine, Inc.

EDIT Quotes by TradingView
  • Ticker EDIT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 68,737,200
  • Market Cap $168M
  • Description
  • Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...
More about EDIT
Track This Portfolio

Track Two Sigma Investments, LP Portfolio

Follow Two Sigma Investments, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Two Sigma Investments, LP, based on Form 13F filings with the SEC.

News

Stay updated on Two Sigma Investments, LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email